SCHEMBL23217544

SCHEMBL23217544

CCOC(=O)c1cc(Br)c2occc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA7 P43166 3/20 0.45
CA9 Q16790 3/20 0.45
CA14 Q9ULX7 3/20 0.45
PTPN11 Q06124 2/20 0.45
BCL2L1 Q07817 1/20 0.44
MAOB P27338 1/20 0.42
ESR1 P03372 3/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ESR2 Q92731 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31026070 1.00 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL643091 0.85 CA12 (0.55) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL5987396 0.84 NOTUM (0.44) ALDH1A1MEN1KMT2AMAPTCA12
SCHEMBL642423 0.80 HSD17B2 (0.45) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL30950146 0.79 MAPT (0.39) ALDH1A1MEN1KMT2AMAPTTSHR
SCHEMBL23217674 0.78 SMN1; SMN2 (0.39) ALDH1A1MAPTMAOBNPC1RAB9A
SCHEMBL31056254 0.78 HSD17B2 (0.43) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL23217832 0.77 MAOB (0.35) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL30010699 0.77 MAOB (0.35) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL5987785 0.77 TTR (0.47) ALDH1A1MEN1KMT2ATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALDH1A1 3388/4885MEN1 659/4885KMT2A 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.